Published in HPB (Oxford) on August 02, 2011
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome. Br J Cancer (2013) 1.02
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB (Oxford) (2012) 0.82
Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int (2015) 0.80
Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases. Proteomes (2016) 0.75
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. Oncotarget (2016) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol (2004) 4.78
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg (2005) 3.04
Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol (2004) 2.95
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol (2006) 2.71
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg (2007) 2.40
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer (2004) 2.19
XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis (2000) 2.16
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg (1999) 1.94
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res (2000) 1.91
Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf (2007) 1.58
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res (2006) 1.49
Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg (2007) 1.42
Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation (2000) 1.42
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics (2002) 1.21
Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg (2007) 1.19
Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J (2005) 1.18
Liver failure after major hepatic resection. J Hepatobiliary Pancreat Surg (2008) 1.16
Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med (2004) 1.09
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res (2003) 1.09
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol (2007) 0.96
Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int (2005) 0.95
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
Participation of iatrogenically coagulopathic patients in wilderness activities. Wilderness Environ Med (2013) 1.96
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res (2011) 1.87
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J (2012) 1.75
Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood (2011) 1.69
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Adjuvant therapy in gastric cancer. J Clin Oncol (2005) 1.56
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res (2004) 1.54
Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J (2013) 1.52
Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract (2008) 1.49
The developing clinical problem of chemotherapy-induced hepatic injury. ANZ J Surg (2011) 1.43
CNS listeriosis confused with leptomeningeal carcinomatosis in a patient with a malignant insulinoma. Am J Clin Oncol (2002) 1.38
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res (2003) 1.38
Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. Brain (2008) 1.35
In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate (2014) 1.35
Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology (2010) 1.33
Patterns of injury in hospitalized terrorist victims. Am J Emerg Med (2003) 1.28
A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res (2006) 1.26
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer (2007) 1.24
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22
Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol (2008) 1.14
Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract (2011) 1.13
Identification of candidate murine esophageal stem cells using a combination of cell kinetic studies and cell surface markers. Stem Cells (2006) 1.11
Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer (2004) 1.11
Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol (2008) 1.10
Esophageal stem cells--a review of their identification and characterization. Stem Cell Rev (2008) 1.08
Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys (2010) 1.06
Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. Mol Cell Biol (2004) 1.05
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int J Cancer (2009) 1.04
Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med (2012) 1.04
Lower gastrointestinal haemorrhage and superselective angiographic embolization. ANZ J Surg (2004) 1.03
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer (2013) 1.02
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.00
Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol (2007) 1.00
Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res (2013) 0.98
Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation (2005) 0.98
Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs (2008) 0.95
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer (2012) 0.93
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res (2014) 0.93
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. Am J Hematol (2015) 0.93
Laparoscopic hepatectomy is a safe procedure for cancer patients. HPB (Oxford) (2009) 0.93
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS One (2012) 0.92
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging (2010) 0.92
Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation. Breast Cancer Res (2005) 0.91
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast (2010) 0.91
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother (2009) 0.90
Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology (2013) 0.90
Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys (2011) 0.90
Long-term outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology (2011) 0.89
Targeted therapies for gastric cancer: current status. Drugs (2011) 0.89
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden. Acta Oncol (2003) 0.89
Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2012) 0.88
A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. Eur J Surg Oncol (2009) 0.88
Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol (2004) 0.87
Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs (2005) 0.87
Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol (2004) 0.86
Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils. Ann Surg Oncol (2010) 0.86
Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res (2011) 0.86
Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol (2009) 0.86
PIK3CA mutations in ovarian cancer. Clin Cancer Res (2005) 0.86
Reversible parkinsonism due to chronic bilateral subdural hematomas. J Clin Neurosci (2009) 0.84
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer (2006) 0.84
Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit (2014) 0.84
Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma. Eur J Surg Oncol (2009) 0.84
Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. Ann Surg Oncol (2014) 0.84
Diagnostic application of Epstein-Barr virus-encoded RNA in situ hybridisation. Pathology (2004) 0.83
Aorto-appendiceal fistula presenting with bleeding per rectum. ANZ J Surg (2004) 0.83
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.83
Understanding how cancer patients actualise, relinquish, and reject advance care planning: implications for practice. Support Care Cancer (2013) 0.83
Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hematol (2012) 0.82
Guidelines for the management of bile duct stones. ANZ J Surg (2008) 0.82
A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol (2011) 0.82
Effectiveness of physical therapy treatments on lateral epicondylitis. J Sport Rehabil (2008) 0.82
18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin's disease: a case report. J Med Case Rep (2011) 0.82
Contrasting effects of elevated temperature and invertebrate grazing regulate multispecies interactions between decomposer fungi. PLoS One (2013) 0.81
Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. J Surg Oncol (2013) 0.81
Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers. Clin Cancer Res (2006) 0.81
Barrett's esophagus: cancer and molecular biology. Ann N Y Acad Sci (2013) 0.81
Fixation-off sensitivity in epilepsies other than the idiopathic epilepsies of childhood with occipital paroxysms: a 12-year clinical-video EEG study. Epileptic Disord (2009) 0.80
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res (2010) 0.80
Advances in understanding the pathogenesis of Barrett's esophagus. Discov Med (2014) 0.80